Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies
暂无分享,去创建一个
[1] A. Carlsson,et al. EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.
[2] M Laruelle,et al. Stability of [123I]IBZM SPECT measurement of amphetamine‐induced striatal dopamine release in humans , 1999, Synapse.
[3] C. Halldin,et al. Changes in striatal D2‐receptor density following chronic treatment with amphetamine as assessed with pet in nonhuman primates , 1999, Synapse.
[4] J S Fowler,et al. Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain , 1999, Synapse.
[5] M Laruelle,et al. Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. , 1998, The American journal of psychiatry.
[6] M. Laruelle. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[7] A. Malhotra,et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach , 1998, Synapse.
[8] J. Krystal,et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.
[9] D. Brooks,et al. Evidence for striatal dopamine release during a video game , 1998, Nature.
[10] Daniel R. Weinberger,et al. Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine , 1998, Nature.
[11] Michael D. Nelson,et al. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging : A meta-analytic study , 1998 .
[12] T. Svensson,et al. Non‐NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK‐801) induced hyperlocomotion and dopamine release in the nucleus accumbens , 1998, Journal of neuroscience research.
[13] Jeffrey A Lieberman,et al. Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity , 1997, Neuropsychopharmacology.
[14] Marc Laruelle,et al. Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.
[15] G D Pearlson,et al. PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects. , 1997, The American journal of psychiatry.
[16] N. Bunnett,et al. Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors. , 1997, The American journal of physiology.
[17] L. Seiden,et al. Evaluation of d‐amphetamine effects on the binding of dopamine D‐2 receptor radioligand, 18F‐fallypride in nonhuman primates using positron emission tomography , 1997, Synapse.
[18] J. Edwardson,et al. Endocytosis and recycling of G protein-coupled receptors. , 1997, Trends in pharmacological sciences.
[19] J. Lieberman,et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. , 1997, Archives of general psychiatry.
[20] W C Eckelman,et al. Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] Christer Halldin,et al. Effect of reserpine‐induced depletion of synaptic dopamine on [11C]Raclopride binding to D2‐dopamine receptors in the monkey brain , 1997, Synapse.
[22] A. Malhotra,et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[23] C. Crouzel,et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients , 1997, Schizophrenia Research.
[24] P B Hoffer,et al. Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.
[25] E. Abercrombie,et al. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats , 1996, Brain Research Bulletin.
[26] J. Krystal,et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[27] B. Bloch,et al. Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation , 1996, Brain Research.
[28] B. Moghaddam,et al. The Prefrontal Cortex Regulates the Basal Release of Dopamine in the Limbic Striatum: An Effect Mediated by Ventral Tegmental Area , 1996, Journal of neurochemistry.
[29] J. Hietala,et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.
[30] Carol A. Tamminga,et al. Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.
[31] J. Bolam,et al. Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[32] D. Charney,et al. Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release , 1995, Schizophrenia Research.
[33] A. D. Smith,et al. Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: Light and electron microscopy , 1995, Neuroscience.
[34] A. Grace,et al. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. , 1995, Drug and alcohol dependence.
[35] T. Robinson,et al. Amphetamine‐Induced time‐dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: A microdialysis study in behaving rats , 1995, Synapse.
[36] J D Brodie,et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[37] Alan C. Evans,et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[38] P B Hoffer,et al. In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography. , 1994, European journal of pharmacology.
[39] P S Goldman-Rakic,et al. D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[40] A C Roberts,et al. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[41] Robert B. Innis,et al. SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: II. Equilibrium Analysis of Constant Infusion Experiments and Correlation with in vitro Parameters , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[42] Jean Logan,et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain , 1994, Synapse.
[43] J. Seibyl,et al. SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[44] V. Lehtinen,et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. , 1994, Archives of general psychiatry.
[45] K. Blum,et al. No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. , 1994, JAMA.
[46] R. Murray,et al. D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients , 1994, British Journal of Psychiatry.
[47] R. G. Manning,et al. Evaluation of 5‐[18F]Fluoropropylepidepride as a potential pet radioligand for imaging dopamine D2 receptors , 1993, Synapse.
[48] D L Price,et al. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[49] P. Kalivas. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area , 1993, Brain Research Reviews.
[50] J S Fowler,et al. Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.
[51] P B Hoffer,et al. Single photon emission tomography measurement of benzodiazepine receptor number and affinity in primate brain: a constant infusion paradigm with [123I]iomazenil. , 1993, European journal of pharmacology.
[52] R R MacGregor,et al. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[53] Marc Laruelle,et al. Amphetamine‐stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates , 1992, Synapse.
[54] K. Davis,et al. Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.
[55] T. Goldberg,et al. Lack of a bimodal distribution of ventricular size in schizophrenia: A Gaussian mixture analysis of 1056 cases and controls , 1991, Biological Psychiatry.
[56] D. Wong,et al. Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain , 1991, Synapse.
[57] Jean Logan,et al. Effects of endogenous dopamine on measures of [18F]N‐methylspiroperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons , 1991, Synapse.
[58] P. Kalivas,et al. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity , 1991, Brain Research Reviews.
[59] J S Fowler,et al. Amphetamine induced decreases in (18F)‐N‐methylspiroperidol binding in the baboon brain using positron emission tomography (PET) , 1991, Synapse.
[60] S. L. Patrick,et al. Concomitant sensitization of amphetamine-induced behavioral stimulation and in vivo dopamine release from rat caudate nucleus , 1991, Brain Research.
[61] Svante B. Ross,et al. Synaptic Concentration of Dopamine in the Mouse Striatum in Relationship to the Kinetic Properties of the Dopamine Receptors and Uptake Mechanism , 1991, Journal of neurochemistry.
[62] L. Parsons,et al. Extracellular Concentrations of Cocaine and Dopamine Are Enhanced During Chronic Cocaine Administration , 1990, Journal of neurochemistry.
[63] S. Stone-Elander,et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.
[64] S. Otsuki,et al. Enhanced extracellular dopamine level may be the fundamental neuropharmacological basis of cross-behavioral sensitization between methamphetamine and cocaine — an in vivo dialysis study in freely moving rats , 1990, Brain Research.
[65] P. Seeman,et al. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[66] D. Segal,et al. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[67] T. Svensson,et al. Local cooling of pre-frontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. , 1989, Acta physiologica Scandinavica.
[68] S. Otsuki,et al. Subchronic methamphetamine treatment enhances methamphetamine- or cocaine-induced dopamine efflux in vivo , 1989, Biological Psychiatry.
[69] T. Robinson,et al. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats , 1988, Brain Research.
[70] A Carlsson,et al. The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[71] P. Seeman,et al. Dopamine receptors in brain and periphery , 1987, Neurochemistry International.
[72] P Riederer,et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[73] J. Lieberman,et al. Prediction of relapse in schizophrenia. , 1987, Archives of general psychiatry.
[74] T. Ljungberg,et al. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis , 1987, Brain Research.
[75] G. Pearlson,et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. , 1986, Science.
[76] A. M. Friedman,et al. Exogenous l-dopa alters spiroperidol binding, in vivo, in the mouse striatum. , 1986, Life sciences.
[77] T. Robinson,et al. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis , 1986, Brain Research Reviews.
[78] B. Angrist,et al. CNS stimulants as tools in the study of schizophrenia , 1984, Trends in Neurosciences.
[79] J. Lieberman,et al. Methylphenidate challenge as a predictor of relapse in schizophrenia. , 1984, The American journal of psychiatry.
[80] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[81] J. Korf,et al. In vivo binding of N-n-propylnorapomorphine in the rat brain: regional localization, quantification in striatum and lack of correlation with dopamine metabolism. , 1983, European journal of pharmacology.
[82] W. Bunney,et al. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. , 1982, The American journal of psychiatry.
[83] D. Sibley,et al. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. , 1982, The Journal of biological chemistry.
[84] K. Fuxe,et al. Regional in vivo binding of [3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors. , 1981, European Journal of Pharmacology.
[85] C. Carter,et al. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats , 1980, Nature.
[86] T. Crow,et al. Molecular pathology of schizophrenia: more than one disease process? , 1980, British medical journal.
[87] P. Seeman,et al. Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains , 1978, Nature.
[88] M. Poulter,et al. INCREASED DOPAMINE-RECEPTOR SENSITIVITY IN SCHIZOPHRENIA , 1978, The Lancet.
[89] S. Snyder,et al. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. , 1977, Science.
[90] S H Snyder,et al. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.
[91] D. Janowsky,et al. Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms. , 1976, Archives of general psychiatry.
[92] P. Seeman,et al. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. , 1975, Science.
[93] S. Udenfriend,et al. Inhibitors of purified beef adrenal tyrosine hydroxylase. , 1965, Biochemical pharmacology.
[94] Peter Herscovitch,et al. Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[95] N. Volkow,et al. Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects , 1998, Neuropsychopharmacology.
[96] P. Kalivas,et al. The pharmacology and neural circuitry of sensitization to psychostimulants. , 1993, Behavioural pharmacology.
[97] J. Lieberman,et al. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. , 1990, Schizophrenia bulletin.
[98] P. Kalivas,et al. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens , 1990, Synapse.
[99] P. Seeman,et al. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.
[100] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.
[101] P. Seeman,et al. Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.
[102] T. Crow,et al. Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. , 1983, Journal of neural transmission. Supplementum.
[103] A. B. Hollingshead,et al. Four factor index of social status , 1975 .
[104] A. Sjoerdsma,et al. BLOCKADE OF ENDOGENOUS NOREPINEPHRINE SYNTHESIS BY ALPHA-METHYL-TYROSINE, AN INHIBITOR OF TYROSINE HYDROXYLASE. , 1965, The Journal of pharmacology and experimental therapeutics.